Tuberous Sclerosis Complex
VIDEO: Cannabidiol linked to improved seizure and nonseizure outcomes in epilepsy
LOS ANGELES — Treatment with cannabidiol led to improved seizure and nonseizure outcomes in patients with various forms of epilepsy, data show.
Cannabidiol linked to better social, executive function in tuberous sclerosis complex
LOS ANGELES — Treatment with cannabidiol in young people with tuberous sclerosis complex led to significant improvements in several cognitive, behavioral and executive domains, data from ongoing survey show.
FDA approves Hyftor for facial angiofibroma in tuberous sclerosis complex
Q&A: Preventive treatment in TSC leads to ‘major reduction’ of epilepsy outcomes
Findings published last month in Annals of Neurology demonstrated that preventive use of vigabatrin, an antiepileptic drug, positively altered the natural history of seizures in infants with tuberous sclerosis complex.
Preventive treatment positively alters ‘natural history of severe infantile epilepsy’
Preventive treatment with vigabatrin effectively altered the natural history of seizures among infants with tuberous sclerosis complex, decreasing the risk for and severity of epilepsy, according to results published in Annals of Neurology.
FDA approves cannabis product to treat seizures related to tuberous sclerosis complex
The FDA recently announced its approval of the cannabis-based Epidiolex, an oral solution to treat seizures in patients aged older than 1 year with tuberous sclerosis complex, a rare genetic disease that causes noncancerous tumors to grow in the brain and other parts of the body.